fbpx

Year

2015
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
93% of patients had full or partial cyst resolution at 12 months. No post-operative infections reported during follow-up period. No fractures reported during the follow-up period
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...
Envarsus® XR is Indicated for Patients Converted from Tacrolimus Immediate-release FormulationsVeloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from immediate release tacrolimus products to once-daily Envarsus® XR. 
Helsinki, 3 December 2015 at 9:30 amRecruitment completed ahead of scheduleNexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that it has successfully completed enrolment of its Phase III NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) clinical trial in stroke therapy,...
Cambridge, UK - 3rd December 2015: Acacia Pharma Group plc (Acacia Pharma"), the supportive care company developing products for US and international markets, today announces that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink."
Sensile Medical wins as Innovation Leader for micropump at core of    sc2Wear Patch Pump– LEXINGTON, MA. November 23,    2015– scPharmaceuticals, Inc. today announced that its strategic partner,    Sensile Medical, was awarded the prestigious Swiss Technology Award in the category    “Innovation Leader.” The prize is the most important distinction    for innovation and technology transfer...
Paris, France - November 12, 2015 - Enterome Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on the gut microbiome, announces that it has entered into a collaborative development agreement with Gustave Roussy, Europe's first comprehensive cancer centre.
Program aims to develop a new method of delivering trusted antibiotic without risk or costs associated with daily intravenous infusions.LEXINGTON, Mass., November 10, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that it has commenced its pivotal trial of subcutaneous administration of the antibiotic ceftriaxone for use with the sc2Wear Patch Pump.  
Doling out over DKK 60 million to ground-breaking research is a good way to spend a Monday evening, and that is what Lundbeck Foundation has chosen to do on Monday, 9 November, when the Foundation celebrates six new Fellows, who will each receive DKK 10 million, and also hands out this year's Research Prize for...
1 2 3 7

News

Open for applications for postdoc scholarships
11. July 2019
Shorter hospital stays after hip and knee surgery
8. July 2019
The Lundbeck Foundation is seeking new fellows
8. July 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge